Matthew C. Dallos

783 total citations
32 papers, 473 citations indexed

About

Matthew C. Dallos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Matthew C. Dallos has authored 32 papers receiving a total of 473 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 17 papers in Immunology. Recurrent topics in Matthew C. Dallos's work include Cancer Immunotherapy and Biomarkers (23 papers), Immunotherapy and Immune Responses (13 papers) and Prostate Cancer Treatment and Research (12 papers). Matthew C. Dallos is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), Immunotherapy and Immune Responses (13 papers) and Prostate Cancer Treatment and Research (12 papers). Matthew C. Dallos collaborates with scholars based in United States, Italy and Spain. Matthew C. Dallos's co-authors include Charles G. Drake, Karie Runcie, Aleksandar Obradović, Brendan Quinn, M. Christine Hollander, Hiroshi Kitagawa, Jessica E. Hawley, Regan M. Memmott, Phillip A. Dennis and Joell J. Gills and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Matthew C. Dallos

30 papers receiving 472 citations

Peers

Matthew C. Dallos

ONCOL

IMMUN

PRM

Xiliang Cong China

Oğuz Bilgi Türkiye

Lijun Xu China

Shuling Han China

Akio Emoto Japan

Wenqing Feng China

Takahiro Toyokawa Japan

Jun Osugi Japan

Massimiliano Grassi Italy

Christophe Van Berckelaer Belgium

Xiliang Cong China

Matthew C. Dallos

283 ×1.0

ONCOL

161 ×0.8

IMMUN

150 ×0.9

PRM

129 ×0.8

112 ×1.8

Citations per year, relative to Matthew C. Dallos Matthew C. Dallos (= 1×) peers Xiliang Cong

Countries citing papers authored by Matthew C. Dallos

Since Specialization

Citations

This map shows the geographic impact of Matthew C. Dallos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew C. Dallos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew C. Dallos more than expected).

Fields of papers citing papers by Matthew C. Dallos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew C. Dallos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew C. Dallos. The network helps show where Matthew C. Dallos may publish in the future.

Co-authorship network of co-authors of Matthew C. Dallos

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew C. Dallos. A scholar is included among the top collaborators of Matthew C. Dallos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew C. Dallos. Matthew C. Dallos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dallos, Matthew C., Aleksandar Obradović, Nivedita Chowdhury, et al.. (2024). Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer. Clinical Cancer Research. 30(22). 5218–5230. 5 indexed citations

Lopez‐Bujanda, Zoila A., et al.. (2024). Chemotactic signaling pathways in prostate cancer: Implications in the tumor microenvironment and as potential therapeutic targets. International review of cell and molecular biology. 388. 162–205. 2 indexed citations

Ager, Casey R., Mingxuan Zhang, Matthew G. Chaimowitz, et al.. (2023). KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response. Journal for ImmunoTherapy of Cancer. 11(9). e006782–e006782. 7 indexed citations

Hawley, Jessica E., Matthew C. Dallos, Emerson A. Lim, et al.. (2023). The PRIME-CUT study: A single-arm phase 2 study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer.. Journal of Clinical Oncology. 41(16_suppl). e17089–e17089. 1 indexed citations

Runcie, Karie, Moshe Chaim Ornstein, Biren Saraiya, et al.. (2023). Assessment of surgical complications in patients with metastatic clear cell renal cell carcinoma (mccRCC) receiving perioperative cabozantinib and nivolumab on Cyto-KIK clinical trial.. Journal of Clinical Oncology. 41(6_suppl). 691–691. 1 indexed citations

Bukhari, Shoiab, Brian S. Henick, Robert Winchester, et al.. (2022). Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Reports Medicine. 4(1). 100868–100868. 41 indexed citations

Tagawa, Scott T., Joseph R. Osborne, Matthew C. Dallos, et al.. (2022). Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 40(6_suppl). TPS216–TPS216. 7 indexed citations

Dallos, Matthew C., Samuel Pan, Matthew G. Chaimowitz, et al.. (2022). A randomized phase Ib/II study of intermittent androgen deprivation therapy plus nivolumab with or without interleukin-8 blockade in men with hormone-sensitive prostate cancer (MAGIC-8).. Journal of Clinical Oncology. 40(16_suppl). 5082–5082. 5 indexed citations

Runcie, Karie, Eric A. Singer, Moshe Chaim Ornstein, et al.. (2021). Phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib) (Cyto-KIK).. Journal of Clinical Oncology. 39(6_suppl). TPS371–TPS371. 1 indexed citations

10.

Aggen, David H., Casey R. Ager, Aleksandar Obradović, et al.. (2020). Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses. Clinical Cancer Research. 27(2). 608–621. 92 indexed citations

11.

Obradović, Aleksandar, Matthew C. Dallos, Marianna Zahurak, et al.. (2020). T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. Clinical Cancer Research. 26(13). 3182–3192. 73 indexed citations

12.

Hawley, Jessica E., Samuel Pan, William D. Figg, et al.. (2020). Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy. The Prostate. 80(4). 336–344. 11 indexed citations

13.

Friedman, Claire F., Paolo A. Ascierto, Diwakar Davar, et al.. (2020). 393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results. SHILAP Revista de lepidopterología. A239.1–A239. 5 indexed citations

14.

Hawley, Jessica E., Aleksandar Obradović, Xinzheng V. Guo, et al.. (2020). Dissecting the immune infiltrate induced by ADT and PD-1 blockade in men with metastatic hormone-sensitive prostate cancer using single-cell RNA-sequencing.. Journal of Clinical Oncology. 38(15_suppl). e17548–e17548. 1 indexed citations

15.

Davar, Diwakar, Matteo Simonelli, Martin Gutierrez, et al.. (2020). 394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results. SHILAP Revista de lepidopterología. A239.2–A240. 13 indexed citations

16.

Dallos, Matthew C., Andrew Eisenberger, & Susan E. Bates. (2019). Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma. The Oncologist. 25(2). 132–139. 17 indexed citations

17.

Dallos, Matthew C., David H. Aggen, Jessica E. Hawley, et al.. (2019). A randomized phase Ib/II study of nivolumab with or without BMS-986253 in combination with a short course of ADT in men with castration-sensitive prostate cancer (MAGIC-8).. Journal of Clinical Oncology. 37(7_suppl). TPS329–TPS329. 3 indexed citations

18.

Dallos, Matthew C., et al.. (2018). Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks. Current Oncology Reports. 20(9). 75–75. 44 indexed citations

19.

Dallos, Matthew C. & Charles G. Drake. (2018). Blocking PD-1/PD-L1 in Genitourinary Malignancies. The Cancer Journal. 24(1). 20–30. 15 indexed citations

20.

Quinn, Brendan, Matthew C. Dallos, Hiroshi Kitagawa, et al.. (2013). Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling. Cancer Prevention Research. 6(8). 801–810. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact